Drug Discovery and Development in notext: Neurostimulation Devices

Publication date: June 2012
Report size: 99 pages

Keywords : Alzheimer's Disease, Chronic Pain, heart failure, epilepsy, urinary incontinence, obesity

Search ReportLinker

The Largest Collection of Market Research Reports

» 1.2 Million Industry Reports
» 450,000 Company Profiles

» 850,000 Market Briefings
» 40,000 Country Guides

From +200,000 authoritative sources

The report provides industry landscape, competitive landscape and industry trends data on the neurostimulation devices industry . The report provides comprehensive data on the major industry developments affecting the industry, and key analytical content on the industry dynamics. The report also reviews the competitive landscape and technology offerings.

Scope of the Research

- Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
- Key sectors covered include Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Vagus Nerve Stimulators and Cortical Stimulators.
- Annualized industry revenues data from 2003 to 2010, projection forward for 7 years to 2017. Firms shares data for 2010.
- Qualitative analysis of key industry trends, industry drivers, and restraints by each category within neurostimulation devices industry .
- The report also covers data on the leading industry players, the competitive landscape, and the leading new product development and technologies.
- Key Companies covered include Medtronic, St. Jude Medical, Boston Scientific Corporation and Cyberonics.

Reasons to buy

- Develop business strategies by understanding the trends and developments that are driving the neurostimulation devices industry globally.
- Design and develop your product development, industry ing and sales strategies.
- Develop successful market-entry strategies .
- Identify key players best positioned to take advantage of the emerging industry opportunities.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- What’s the next big thing in the neurostimulation devices industry landscape? – Identify, understand and decide.
- Make more informed business decisions from the insightful and in-depth analysis of the global neurostimulation devices industry and the factors shaping it.

Global Pathology Industry

1 Table of contents

I Table of contents 3
I. 1 List of Data tables 6
I. 2 List of Charts 8

II Introduction and Overview 9
II. 1 GlobalData Report Guidance 9
3 Disease Data 10
III. 1 Disease Data - Chronic Pain 10
III. 1.1 Introduction 10
III. 1.2 Causes of Chronic Pain 11
III. 1.3 Signs and Symptoms 11
III. 1.4 Treatment 11
III. 1.5 Epidemiology 12
III. 2 Disease Data - Parkinson’s Disease 12
III. 2.1 Introduction 12
III. 2.2 Causes of Parkinson’s Disease 12
III. 2.3 Signs and Symptoms 13
III. 2.4 Treatment 14
III. 2.5 Epidemiology 14
III. 3 Disease Data - Epilepsy 15
III. 3.1 Introduction 15
III. 3.2 Causes of Epilepsy 15
III. 3.3 Signs and Symptoms 15
III. 3.4 Treatment 15
III. 3.5 Epidemiology 16

IV Neurostimulation Devices Overview 17
IV. 1 Technology Overview 17
IV. 1.1 Introduction 17
IV. 1.2 Types of Neurostimulation Systems 17
IV. 1.3 Applications of Neurostimulation Devices 18
IV. 1.4 Neurostimulation Devices, March ket Segmentation 18

V Neurostimulation Devices - World March ket Characterization 20
V. 1 Neurostimulation Devices March ket, Global, Sales (USD Million), Historical data, 2003?2010 20
V. 2 Neurostimulation Devices March ket, Global, Sales (USD Million), Forecasted data, 2010?2017 21
V. 3 Neurostimulation Device, Key Trends 22
V. 3.1 Application of Neurostimulation Technology for the Treatment of New Indications 22
V. 3.2 Neurostimulation Devices March ket is Witnessing Increasing Innovation 24
V. 3.3 Technological Advances such as Increased Battery Life have led to an Increase in the Adoption of Neurostimulation Devices 24
V. 4 Neurostimulation Devices, March ket Dynamics 25
V. 4.1 March ket Drivers 25
V. 4.2 March ket Restraints 31
V. 5 Neurostimulation Devices, Key Opportunities (SWOT Analysis) and Unmet Needs 32
V. 5.1 Opportunities (SWOT Analysis) 32
V. 5.2 Unmet Needs 33
6 World Neurostimulation Devices March ket: Segment Analysis 34
VI. 1 Spinal Cord Stimulators, March ket Characterization 34
VI. 1.1 Spinal Cord Stimulators March ket, Sales (USD Million), Historical data, from 2003 to 2010 34
VI. 1.2 Spinal Cord Stimulators March ket, Sales (USD Million), Forecasted data, from 2010 to 2017 35
VI. 1.3 Spinal Cord Stimulators, March ket Dynamics 36
VI. 2 Deep Brain Stimulators, March ket Characterization 37
VI. 2.1 Deep Brain Stimulators March ket, Sales (USD Million), Historical data, 2003 ? 2010 37
VI. 2.2 Deep Brain Stimulators March ket, Sales (USD Million), Forecasted data, from 2010 to 2017 38
VI. 2.3 Deep Brain Stimulators, March ket Dynamics 39
VI. 3 Sacral Nerve Stimulators, March ket Characterization 40
VI. 3.1 Sacral Nerve Stimulators March ket, Sales (USD Million), Historical data, from 2003 to 2010 40
VI. 3.2 Sacral Nerve Stimulators March ket, Sales (USD Million), Forecasted data, from 2010 to 2017 41
VI. 3.3 Sacral Nerve Stimulators, March ket Dynamics 42
VI. 4 Vagus Nerve Stimulators, March ket Characterization 43
VI. 4.1 Vagus Nerve Stimulators March ket, Sales (USD Million), Historical data, from 2003 to 2010 43
VI. 4.2 Vagus Nerve Stimulators March ket, Sales (USD Million), Forecasted data, from 2010 to 2017 44
VI. 4.3 Vagus Nerve Stimulators, March ket Dynamics 45
VI. 5 Cortical Stimulators, March ket Characterization 46
VI. 5.1 Cortical Stimulators March ket, Sales (USD Million), Historical data, from 2003 to 2010 46
VI. 5.2 Cortical Stimulators March ket, Sales s (USD Million), Forecasted data, from 2010 to 2017 47
VI. 5.3 Cortical Stimulators, March ket Dynamics 47

VII Neurostimulation Devices March ket, by Country, Sales (USD Million), from 2003 to 2017 48
VII. 1 Neurostimulation Devices March ket, The US, Sales (USD Million), By Segment, Historical data, from 2003 to 2010 48
VII. 2 Neurostimulation Devices March ket, The US, Sales (USD Million), By Segment, Forecasted data, from 2010 to 2017 49
VII. 3 Neurostimulation Devices March ket, Canada, Sales (USD Million), By Segment, Historical data, from 2003 to 2010 50
VII. 4 Neurostimulation Devices March ket, Canada, Sales (USD Million), By Segment, Forecasted data, 2010–2017 51
VII. 5 Neurostimulation Devices March ket, The UK, Sales (USD Million), By Segment, Historical data, 2003–2010 52
VII. 6 Neurostimulation Devices March ket, The UK Sales (USD Million), By Segment, Forecasted data, 2010–2017 53
VII. 7 Neurostimulation Devices March ket, Germany, Sales (USD Million), By Segment, Historical data, 2003–2010 54
VII. 8 Neurostimulation Devices March ket, Germany, Sales (USD Million), By Segment, Forecasted data, 2010–2017 55
VII. 9 Neurostimulation Devices March ket, France, Sales (USD Million), By Segment, Historical data, from 2003 to 2010 56
VII. 10 Neurostimulation Devices March ket, France, Sales (USD Million), By Segment, Forecasted data, 2010–2017 57
VII. 11 Neurostimulation Devices March ket, Italy, Sales (USD Million), By Segment, Historical data, 2003–2010 58
VII. 12 Neurostimulation Devices March ket, Italy, Sales (USD Million), By Segment, Forecasted data, 2010–2017 59
VII. 13 Neurostimulation Devices March ket, Spain, Sales (USD Million), By Segment, Historical data, from 2003 to 2010 60
VII. 14 Neurostimulation Devices March ket, Spain, Sales (USD Million), By Segment, Forecasted data, from 2010 to 2017 61
VII. 15 Neurostimulation Devices March ket, Japan, Sales (USD Million), By Segment, Historical data, from 2003 to 2010 62
VII. 16 Neurostimulation Devices March ket, Japan, Sales (USD Million), By Segment, Forecasted data, from 2010 to 2017 63
VII. 17 Neurostimulation Devices March ket, China, Sales (USD Million), By Segment, Historical data, from 2003 to 2010 64
VII. 18 Neurostimulation Devices March ket, China, Sales (USD Million), By Segment, Forecasted data, from 2010 to 2017 65
VII. 19 Neurostimulation Devices March ket, India, Sales (USD Million), By Segment, Historical data, from 2003 to 2010 66
VII. 20 Neurostimulation Devices March ket, India, Sales (USD Million), By Segment, Forecasted data, from 2010 to 2017 67
VII. 21 Neurostimulation Devices March ket, Australia, Sales (USD Million), By Segment, Historical data, from 2003 to 2010 68
VII. 22 Neurostimulation Devices March ket, Australia, Sales (USD Million), By Segment, Forecasted data, from 2010 to 2017 69
VII. 23 Neurostimulation Devices March ket, Brazil, Sales (USD Million), By Segment, Historical data, from 2003 to 2010 70
VII. 24 Neurostimulation Devices March ket, Brazil, Sales (USD Million), By Segment, Forecasted data, from 2010 to 2017 71

VIII Neurostimulation Devices March ket - Competitive Landscape 72
VIII. 1 Neurostimulation Devices March ket, Key Market Shares (%), 2010 72
VIII. 2 Neurostimulation Devices March ket, Key March ket Participants 73
VIII. 2.1 Medtronic, Inc. 73
VIII. 2.2 St. Jude Medical 78
VIII. 2.3 Boston Scientific Corporation 81
VIII. 2.4 Cyberonics, Inc. 83

IX Neurostimulation Devices March ket - Key March keted Products 86
IX. 1 PrimeAdvanced Neurostimulator (Medtronic, Inc.) 86
IX. 1.1 Product Description 86
IX. 1.2 Product Features 86
IX. 2 Activa Portfolio of DBS systems (Medtronic, Inc.) 86
IX. 2.1 Product Description 86
IX. 2.2 Product Features 87
IX. 3 Precision Plus SCS System (Boston Scientific Corporation) 87
IX. 3.1 Product Description 87
IX. 3.2 Product Features 87
IX. 4 Brio Rechargeable IPG (St. Jude Medical) 88
IX. 4.1 Product Description 88
IX. 4.2 Product Features 88
IX. 5 Eon-Mini Rechargeable IPG system (St. Jude Medical) 88
IX. 5.1 Product Description 88
IX. 5.2 Product Features 88

X Neurostimulation Devices March ket - Strategic Pipeline Assessment 89
X. 1 Pipeline Products Assessment for Neurostimulation Devices by Development Stage, Global, 2010 89
X. 2 Neurostimulation Devices - Profiles of Key Pipeline Products Under Clinical Development 89
X. 2.1 Active Implantable Device- Parkinson’s Disease 89
X. 2.2 Balance System 89
X. 2.3 Biocompatible Neural Electrode 90
X. 2.4 Bioness Battery Powered Microstimulator 90
X. 2.5 CardioFit System 92
X. 2.6 CR Brain 93
X. 2.7 Deep TMS H System 93
X. 2.8 Enterra-Obesity 99
X. 2.9 Intercept Epilepsy Control System 100
X. 2.10 Ischemic Stroke System 101
X. 2.11 Libra Deep Brain Stimulation System - Depression 102
X. 2.12 Neurostep 103
X. 2.13 Noninvasive Device - Sensory Enhancement Technology 105
X. 2.14 Occipital Nerve Stimulation System 106
X. 2.15 Pain Therapy Device 108
X. 2.16 PrimeADVANCED- Heart Failure 109
X. 2.17 Resolve Stimulator and Proximity Electrode 110
X. 2.18 RNS System 112
X. 2.19 ScyFIX 700 Therapy 115
X. 2.20 Transcranial Magnetic Stimulation Device 118
X. 2.21 Traxon Spinal Cord Repair Stimulation System 119
X. 2.22 Vercise DBS System 120

XI Neurostimulation Devices March ket: Deals Landscape 121
XI. 1 Neurostimulation Devices March ket, Merger and Acquisition Landscape 122
XI. 1.1 Key Acquisitions 122
XI. 2 Neurostimulation Devices March ket, Partnership Deals 124
XI. 2.1 Key Partnership Deals 124

XII Appendix 126
XII. 1 March ket Definitions 126
XII. 1.1 Neurostimulation Devices 126
XII. 2 Acronyms 127
XII. 3 Sources 128
XII. 4 Research Methodology 129
XII. 4.1 Secondary Research 129
XII. 4.2 Primary Research 129
XII. 4.3 Models 130
XII. 4.4 Forecasted data s 130
XII. 4.5 Expert Panel 130
XII. 5 GlobalData Consulting 130
XII. 6 Contact Us 131
XII. 7 Disclaimer 131

1.1

List of Tables

Data table 1: Deep Brain Stimulators, Key March keted Products 18
Data table 2: Spinal Cord Stimulators, Key March keted Products 19
Data table 3: Neurostimulation Devices March ket, Global, Sales (USD Million), from 2003 to 2010 20
Data table 4: Neurostimulation Devices March ket, Global, Sales (USD Million), from 2010 to 2017 21
Data table 5: Pipeline Products In-Development for New Indications 23
Data table 6: Population Aged 65 Years and Over, Global, %, 2010 26
Data table 7: Neurostimulation Devices March ket, Global, PE/VC Deals, 2006?2010 28
Data table 8: Neurostimulation Devices, Global, Average Selling Price ($), 2010 31
Data table 9: Spinal Cord Stimulators March ket, Global, Sales (USD Million), from 2003 to 2010 34
Data table 10: Spinal Cord Stimulators March ket, Global, Sales (USD Million), from 2010 to 2017 35
Data table 11: Deep Brain Stimulators March ket, Global, Sales (USD Million), from 2003 to 2010 37
Data table 12: Deep Brain Stimulators March ket, Global, Sales (USD Million), from 2010 to 2017 38
Data table 13: DBS Pipeline Products 39
Data table 14: Sacral Nerve Stimulators March ket, Global, Sales (USD Million), from 2003 to 2010 40
Data table 15: Sacral Nerve Stimulators March ket, Global, Sales (USD Million), from 2010 to 2017 41
Data table 16: Vagus Nerve Stimulators March ket, Global, Sales (USD Million), from 2003 to 2010 43
Data table 17: Vagus Nerve Stimulators March ket, Global, Sales (USD Million), from 2010 to 2017 44
Data table 18: Cortical Stimulators March ket, Global, Sales (USD Million), from 2003 to 2010 46
Data table 19: Cortical Stimulators March ket, Global, Sales (USD Million), from 2010 to 2017 47
Data table 20: Neurostimulation Devices March ket, The US, Sales (USD Million), from 2003 to 2010 48
Data table 21: Neurostimulation Devices March ket, The US, Sales (USD Million), from 2010 to 2017 49
Data table 22: Neurostimulation Devices March ket, Canada, Sales (USD Million), from 2003 to 2010 50
Data table 23: Neurostimulation Devices March ket, Canada, Sales (USD Million), from 2010 to 2017 51
Data table 24: Neurostimulation Devices March ket, The UK, Sales (USD Million), from 2003 to 2010 52
Data table 25: Neurostimulation Devices March ket, The UK, Sales (USD Million), from 2010 to 2017 53
Data table 26: Neurostimulation Devices March ket, Germany, Sales (USD Million), from 2003 to 2010 54
Data table 27: Neurostimulation Devices March ket, Germany, Sales (USD Million), from 2010 to 2017 55
Data table 28: Neurostimulation Devices March ket, France, Sales (USD Million), from 2003 to 2010 56
Data table 29: Neurostimulation Devices March ket, France, Sales (USD Million), from 2010 to 2017 57
Data table 30: Neurostimulation Devices March ket, Italy, Sales (USD Million), from 2003 to 2010 58
Data table 31: Neurostimulation Devices March ket, Italy, Sales (USD Million), from 2010 to 2017 59
Data table 32: Neurostimulation Devices March ket, Spain, Sales (USD Million), from 2003 to 2010 60
Data table 33: Neurostimulation Devices March ket, Spain, Sales (USD Million), from 2010 to 2017 61
Data table 34: Neurostimulation Devices March ket, Japan, Sales (USD Million), from 2003 to 2010 62
Data table 35: Neurostimulation Devices March ket, Japan, Sales (USD Million), from 2010 to 2017 63
Data table 36: Neurostimulation Devices March ket, China, Sales (USD Million), from 2003 to 2010 64
Data table 37: Neurostimulation Devices March ket, China, Sales (USD Million), from 2010 to 2017 65
Data table 38: Neurostimulation Devices March ket, India, Sales (USD Million), from 2003 to 2010 66
Data table 39: Neurostimulation Devices March ket, India, Sales (USD Million), from 2010 to 2017 67
Data table 40: Neurostimulation Devices March ket, Australia, Sales (USD Million), from 2003 to 2010 68
Data table 41: Neurostimulation Devices March ket, Australia, Sales (USD Million), from 2010 to 2017 69
Data table 42: Neurostimulation Devices March ket, Brazil, Sales (USD Million), from 2003 to 2010 70
Data table 43: Neurostimulation Devices March ket, Brazil, Sales (USD Million), from 2010 to 2017 71
Data table 44: World Neurostimulation Devices March ket, Market Shares, Sales (USD Million), 2010 72
Data table 45: Medtronic, Neurostimulators, March keted Products 73
Data table 46: Medtronic, Neurostimulators, Pipeline Products 74
Data table 47: St. Jude Medical, Neurostimulators, March keted Products 78
Data table 48: St. Jude Medical, Neurostimulators, Pipeline Products 78
Data table 49: Boston Scientific, Neurostimulators, Pipeline Products 81
Data table 50: Cyberonics, Neurostimulators, March keted Products 83
Data table 51: Cyberonics, Neurostimulators, Pipeline Products 83
Data table 52: PrimeAdvanced Neurostimulator, Features and Benefits 86
Data table 53: Activa DBS systems, Features and Benefits 87
Data table 54: Precision Plus SCS system, Features and Benefits 87
Data table 55: Brio Rechargeable IPG, Features and Benefits 88
Data table 56: Eon Mini Rechargeable IPG system, Features and Benefits 88
Data table 57: Balance System, Clinical Trial 90
Data table 58: Bioness Battery Powered Microstimulator, Clinical Trial 91
Data table 59: CardioFit System, Clinical Trial 92
Data table 60: CardioFit System, Clinical Trial 93
Data table 61: Deep TMS H System, Clinical Trial 94
Data table 62: Deep TMS H System, Clinical Trial 95
Data table 63: Deep TMS H System, Clinical Trial 96
Data table 64: Deep TMS H System, Clinical Trial 97
Data table 65: Deep TMS H System, Clinical Trial 98
Data table 66: Enterra-Obesity, Clinical Trial 99
Data table 67: Intercept Epilepsy Control System, Clinical Trial 100
Data table 68: Ischemic Stroke System, Clinical Trial 101
Data table 69: Ischemic Stroke System, Clinical Trial 102
Data table 70: Libra Deep Brain Stimulation System, Clinical Trial 103
Data table 71: Neurostep, Clinical Trial 104
Data table 72: Non-invasive Device - Sensory Enhancement, Clinical Trial 105
Data table 73: Occipital Nerve Stimulation System, Clinical Trial 106
Data table 74: Occipital Nerve Stimulation System, Clinical Trial 107
Data table 75: Pain Therapy Device, Clinical Trial 108
Data table 76: PrimeADVANCED-Heart Failure, Clinical Trial 109
Data table 77: Resolve Stimulator and Proximity Electrode, Clinical Trial 110
Data table 78: Resolve Stimulator and Proximity Electrode, Clinical Trial 111
Data table 79: RNS System, Clinical Trial 112
Data table 80: RNS System, Clinical Trial 113
Data table 81: RNS System, Clinical Trial 114
Data table 82: ScyFIX 700 Therapy, Clinical Trial 115
Data table 83: ScyFIX 700 Therapy, Clinical Trial 116
Data table 84: ScyFIX 700 Therapy, Clinical Trial 116
Data table 85: ScyFIX 700 Therapy, Clinical Trial 117
Data table 86: ScyFIX 700 Therapy, Clinical Trial 117
Data table 87: Transcranial Magnetic Stimulation (TMS) Device, Clinical Trial 118
Data table 88: Traxon Spinal Cord Repair Stimulation System, Clinical Trial 119
Data table 89: Vercise DBS System, Clinical Trial 120
Data table 90: Neurostimulation Devices March ket, Global, Deals Overview, from 2006 to 2011 121
Data table 91: Neurostimulation Devices March ket, Global, Partnership Landscape, 2006?2010 124

1.2

List of Figures

Chart 1: Classification of Pain 10
Chart 2: Types of Neurostimulation Devices 18
Chart 3: Neurostimulation Devices March ket, Global, Sales (USD Million), from 2003 to 2010 20
Chart 4: Neurostimulation Devices March ket, Global, Sales (USD Million), from 2010 to 2017 21
Chart 5: Indications of Neurostimulation Devices 22
Chart 6: Neurostimulation Devices, Closed Loop System 24
Chart 7: Neurostimulation Devices March ket, Global, PE/VC Deals, 2006?2010 28
Chart 8: Risks Associated with Neurostimulation Devices 33
Chart 9: Spinal Cord Stimulators March ket, Global, Sales (USD Million), from 2003 to 2010 34
Chart 10: Spinal Cord Stimulators March ket, Global, Sales (USD Million), from 2010 to 2017 35
Chart 11: Deep Brain Stimulators March ket, Global, Sales (USD Million), from 2003 to 2010 37
Chart 12: Deep Brain Stimulators March ket, Global, Sales (USD Million), from 2010 to 2017 38
Chart 13: Sacral Nerve Stimulators March ket, Global, Sales (USD Million), from 2003 to 2010 40
Chart 14: Sacral Nerve Stimulators March ket, Global, Sales (USD Million), from 2010 to 2017 41
Chart 15: Vagus Nerve Stimulators March ket, Global, Sales (USD Million), from 2003 to 2010 43
Chart 16: Vagus Nerve Stimulators March ket, Global, Sales (USD Million), from 2010 to 2017 44
Chart 17: Cortical Stimulators March ket, Global, Sales (USD Million), from 2003 to 2010 46
Chart 18: Cortical Stimulators March ket, Global, Sales (USD Million), from 2010 to 2017 47
Chart 19: Neurostimulation Devices March ket, The US, Sales (USD Million), from 2003 to 2010 48
Chart 20: Neurostimulation Devices March ket, The US, Sales (USD Million), from 2010 to 2017 49
Chart 21: Neurostimulation Devices March ket, Canada, Sales (USD Million), from 2003 to 2010 50
Chart 22: Neurostimulation Devices March ket, Canada, Sales (USD Million), from 2010 to 2017 51
Chart 23: Neurostimulation Devices March ket, The UK, Sales (USD Million), from 2003 to 2010 52
Chart 24: Neurostimulation Devices March ket, The UK, Sales (USD Million), from 2010 to 2017 53
Chart 25: Neurostimulation Devices March ket, Germany, Sales (USD Million), from 2003 to 2010 54
Chart 26: Neurostimulation Devices March ket, Germany, Sales (USD Million), from 2010 to 2017 55
Chart 27: Neurostimulation Devices March ket, France, Sales (USD Million), from 2003 to 2010 56
Chart 28: Neurostimulation Devices March ket, France, Sales (USD Million), from 2010 to 2017 57
Chart 29: Neurostimulation Devices March ket, Italy, Sales (USD Million), from 2003 to 2010 58
Chart 30: Neurostimulation Devices March ket, Italy, Sales (USD Million), from 2010 to 2017 59
Chart 31: Neurostimulation Devices March ket, Spain, Sales (USD Million), from 2003 to 2010 60
Chart 32: Neurostimulation Devices March ket, Spain, Sales (USD Million), from 2010 to 2017 61
Chart 33: Neurostimulation Devices March ket, Japan, Sales (USD Million), from 2003 to 2010 62
Chart 34: Neurostimulation Devices March ket, Japan, Sales (USD Million), from 2010 to 2017 63
Chart 35: Neurostimulation Devices March ket, China, Sales (USD Million), from 2003 to 2010 64
Chart 36: Neurostimulation Devices March ket, China, Sales (USD Million), from 2010 to 2017 65
Chart 37: Neurostimulation Devices March ket, India, Sales (USD Million), from 2003 to 2010 66
Chart 38: Neurostimulation Devices March ket, India, Sales (USD Million), from 2010 to 2017 67
Chart 39: Neurostimulation Devices March ket, Australia, Sales (USD Million), from 2003 to 2010 68
Chart 40: Neurostimulation Devices March ket, Australia, Sales (USD Million), from 2010 to 2017 69
Chart 41: Neurostimulation Devices March ket, Brazil, Sales (USD Million), from 2003 to 2010 70
Chart 42: Neurostimulation Devices March ket, Brazil, Sales (USD Million), from 2010 to 2017 71
Chart 43: World Neurostimulation Devices March ket, Market Shares (%), 2010 72
Chart 44: Neurostimulation Devices March ket, Medtronic, SWOT 74
Chart 45: Neurostimulation Devices March ket, St. Jude Medical, SWOT 79
Chart 46: Neurostimulation Devices March ket, Boston Scientific, SWOT 81
Chart 47: Neurostimulation Devices March ket, Cyberonics, SWOT 84
Chart 48: Neurostimulation Devices, Pipeline Products, By Development Stage 89
Chart 49: Neurostimulation Devices March ket, Global, Deals Overview, from 2006 to 2011 121
Chart 50: Neurostimulation Devices March ket, Global, Merger and Acquisition Landscape 122

Companies Mentioned
Medtronic, Inc.
St. Jude Medical
Boston Scientific Corporation
Cyberonics, Inc.

Neurological Disease in World